Lifordi Immunotherapeutics Presents Promising Preclinical Data for Autoimmune Treatment LFD-200
TL;DR
Lifordi's LFD-200 ADC technology offers a competitive edge by delivering steroid efficacy without systemic toxicity, potentially capturing significant autoimmune treatment market share.
Lifordi's LFD-200 uses antibody drug conjugate technology to selectively deliver glucocorticoids to immune cells through VISTA targeting, achieving sustained anti-inflammatory effects without systemic toxicity.
Lifordi's LFD-200 could improve autoimmune patients' quality of life by providing safer, less frequently dosed steroid treatments with reduced side effects.
Lifordi's innovative antibody drug conjugate delivers steroids directly to immune cells, achieving targeted treatment effects without the typical systemic toxicity concerns.
Lifordi Immunotherapeutics, Inc. will present additional preclinical data on its lead candidate LFD-200, an antibody drug conjugate designed for treating autoimmune and inflammatory disorders. The new findings from multiple in vitro and in vivo studies in non-human primates demonstrate that LFD-200 achieves targeted and sustained delivery of its glucocorticoid payload to immune cells while showing no concurrent safety signals. This approach aims to provide the efficacy of traditional steroids without the systemic toxicity that often limits their long-term use.
The data will be presented at the American College of Rheumatology Convergence 2025 meeting scheduled for October 24-29 in Chicago. Consistent with prior studies, these new results show that LFD-200 provides targeted anti-inflammatory effects and maintains a favorable safety profile at clinically relevant doses. Specifically, the ADC selectively delivered glucocorticoids to immune tissues and resulted in inhibition of ex vivo induced inflammatory cytokines with no observed systemic toxicity.
LFD-200 represents a significant advancement in autoimmune treatment by potentially offering patients a safer, less frequently dosed glucocorticoid treatment option. The company's approach leverages the success of antibody drug conjugates, traditionally used in oncology, to address the unique challenges of autoimmune and inflammatory disorders. For more information about the company's research and development efforts, visit https://www.lifordi.com.
The poster presentation, titled "LFD-200, an Antibody Drug Conjugate that Selectively Delivers a Glucocorticoid Payload to Immune Cells, Provides Sustained Anti-inflammatory Effects Without Systemic Toxicity in Non-human Primates," will be part of the Rheumatoid Arthritis – Treatment Poster I session on Sunday, October 26, 2025. Lifordi's lead ADC candidate is currently in a Phase 1 clinical trial and has demonstrated efficacy in multiple preclinical disease models by targeting myeloid and lymphoid cells using VISTA, a highly internalized cell surface membrane protein.
The implications of this research extend beyond rheumatoid arthritis to potentially benefit patients with various autoimmune conditions who currently face the difficult choice between disease control and medication side effects. By enabling targeted delivery of potent anti-inflammatory agents directly to immune cells, LFD-200 could revolutionize how autoimmune diseases are managed, reducing the burden of frequent dosing and minimizing the systemic complications that often accompany conventional steroid therapies.
Curated from Reportable